Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.
Andrew P McGovernMichael HoggBeverley M ShieldsNaveed A SattarRury R HolmanEwan R PearsonAndrew T HattersleyAngus G JonesJohn M Dennisnull nullPublished in: BMJ open diabetes research & care (2021)
Female sex and history of prior infection are simple features that can identify subgroups at greatly increased risk of genital infections with SGLT2i therapy. These data can be used to risk-stratify patients. High HbA1c is not a risk factor for genital infections with SGLT2i.